Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.84
+0.40003.22%
Post-market: 13.020.1800+1.40%19:50 EDT
Volume:3.35M
Turnover:43.22M
Market Cap:1.80B
PE:-3.84
High:13.13
Open:12.65
Low:12.65
Close:12.44
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:0.92
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.47
PE(LYR):-3.37

Loading ...

William Blair Upgrades Intellia Therapeutics to Outperform From Market Perform

MT Newswires Live
·
Mar 03

Intellia Therapeutics upgraded at William Blair after clinical hold lifted

TIPRANKS
·
Mar 03

Stock Track | Intellia Therapeutics Soars 5.01% Intraday After FDA Lifts Clinical Hold on Heart Disease Gene Therapy Trial

Stock Track
·
Mar 02

Analysts Conflicted on These Healthcare Names: Denali Therapeutics (DNLI), Eton Pharmaceuticals (ETON) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Mar 02

Stock Track | Intellia Therapeutics Plummets 5.07% Intraday as ATM Offering Expansion Offsets FDA Clinical Hold Lift

Stock Track
·
Mar 02

BUZZ-U.S. STOCKS ON THE MOVE -Duolingo, AES, NextDecade

Reuters
·
Mar 02

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Intellia Therapeutics (NTLA) and Immunic (IMUX)

TIPRANKS
·
Mar 02

BRIEF-Intellia Therapeutics Inc - Increases At-The-Market Offering Program To $1.04 Billion- SEC Filing

Reuters
·
Mar 02

Intellia Therapeutics Inc - Increases at-the-Market Offering Program to $1.04 Bln- SEC Filing

THOMSON REUTERS
·
Mar 02

Intellia Shares Jump Premarket After FDA Removes Hold on Clinical Trial

Dow Jones
·
Mar 02

Intellia Therapeutics Shares Gain 7% Premarket After US FDA Lifts Clinical Hold on Co's Heart Disease Gene Therapy Trial

THOMSON REUTERS
·
Mar 02

US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

Reuters
·
Mar 02

Stock Track | Intellia Therapeutics Soars 6.24% in Pre-market on Analyst Bullish Call

Stock Track
·
Mar 02

Intellia Says FDA Lifts Clinical Hold on MAGNITUDE Phase 3 ATTR-CM Trial

Reuters
·
Mar 02

Intellia Therapeutics Announces FDA Lift of Clinical Hold on Magnitude Phase 3 Clinical Trial in Attr-Cm

THOMSON REUTERS
·
Mar 02

H.C. Wainwright Remains a Buy on Intellia Therapeutics (NTLA)

TIPRANKS
·
Mar 02

Intellia Therapeutics Eyes 2026 Pivotal CRISPR Milestone

TIPRANKS
·
Feb 28

Intellia Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Feb 27

Wedbush Raises Price Target on Intellia Therapeutics to $12 From $7, Keeps Neutral Rating

MT Newswires Live
·
Feb 27

Stock Track | Intellia Therapeutics Plunges 5.46% After-Hours Despite Earnings Beat on Cash Burn and Clinical Hold Concerns

Stock Track
·
Feb 27